Mupirocin

Mupirocin

CAS Number
12650-69-0
Molecular Formula
C26H44O9
IrritantIrritant
Target Host: Pseudomonas fluorescensCDMO Stage: Fermentation Scale-up → Advanced Filtration → Isolation

About Mupirocin

Mupirocin is an FDA-approved topical antibacterial active ingredient widely prescribed throughout the United States for treating impetigo and secondary skin infections and eradicating nasal colonization of methicillin-resistant Staphylococcus aureus (MRSA). We supply commercial and pharmaceutical-grade pseudomonic acid...

Synonyms

  • Bactroban Nasal
  • mupricin
  • Dihydro Mupirocin
  • Mupirocin calcium
  • Mupirocin, 14C-Labeled

Mupirocin Specifications

CAS Number
12650-69-0
Molecular Formula
C26H44O9
Molecular Weight
500.6 g/mol
IUPAC NameORBotanical Name
9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
Canonical SMILES
C[C@H]([C@H]1[C@@H](O1)C[C@H]2CO[C@H]([C@@H]([C@@H]2O)O)C/C(=C/C(=O)OCCCCCCCCC(=O)O)/C)[C@H](C)O
InChI Key
MINDHVHHQZYEEK-HBBNESRFSA-N
InChI
InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1
UNII Code
D0GX863OA5
ChEBI ID
CHEBI:7025
HMDB ID
HMDB0014554
DSSTox Substance ID
DTXSID0046438
EINECS Number
603-145-3
MDL Number
MFCD01711620
Molecular Weight
500.6 g/mol
XLogP3
3
Hydrogen Bond Donor Count
4
Hydrogen Bond Acceptor Count
9
Rotatable Bond Count
17
Exact Mass
500.29853298 Da
Monoisotopic Mass
500.29853298 Da
Melting Point (Experimental)
77-78 °C
Boiling Point (Predicted)
672.313±55.00°C Press: 760.00 Torr
Density (Predicted)
1.183±0.06 g/cm3 Temp: 25 °C; Press: 760 Torr
pKa (Experimental)
4.83
GHS Hazard Statements
H302 (25%): Harmful if swallowed H315 (25%): Causes skin irritation H317 (50%): May cause an allergic skin reaction H319 (25%): Causes serious eye irritation
Hazard Classes and Categories
Acute Tox. 4 (25%) Skin Sens. 1 (50%)

Topical Treatment for Primary Skin Infections

A core active ingredient in 2% topical ointments and creams prescribed for impetigo caused by Staphylococcus aureus and Streptococcus pyogenes

Nasal MRSA Decolonisation Therapy

A specialised active pharmaceutical ingredient formulated into 2% nasal ointments used for preoperative clearance and hospital infection control

Secondary Skin Infection Management

An active antibacterial component utilised in dermatological preparations treating infected traumatic skin lesions, lacerations, and sutured wounds

Fermentation Scale-Up & CDMO Active Production

A benchmark natural product metabolite produced via Pseudomonas fluorescens submerged fermentation for global CDMO commercial supply

Biochemical Research & Protein Synthesis Studies

A high-specificity biochemical tool compound used to investigate bacterial RNA translation, isoleucyl-tRNA synthetase enzyme kinetics, and resistance mechanisms.

  1. Bactroban Nasal
  2. mupricin
  3. Dihydro Mupirocin
  4. Mupirocin calcium
  5. Mupirocin, 14C-Labeled

Mupirocin FAQs

Minimum Order Quantity

25 kg (evaluation) · 1 MT (commercial)

Lead Time

3 – 5 weeks estimated

Delivery Terms

FOB*

Packaging

20 L pails, 200 L HDPE drums, 1000 L IBC

US Availability

US Facility Inventory

Documentation

US SDS · COA · TDS · Specification sheet

US Regulatory & Quality Information

TSCA status*

US SDS / HazCom*

GHS classification*

ISO 9001:2015 site*

DOT shipping classification*

FDA status*

EPA status*

California Prop 65*

Reliable US supply chain

Regulatory compliance

On-time delivery

Technical expert support

Rounded Top

Explore Biologics Portfolio

Leuprolide Acetate

CAS No 74381-53-6

Leuprolide Acetate

Category

Synthetic & Recombinant Peptides

Sub-Category

GnRH Agonists & Oligopeptides

Description : Leuprolide acetate (CAS No: 74381-53-6) is a synthetic nonapeptide analogue of naturally occurring gonadotropin-releasing hormone (GnRH/LHRH) featuring a D-leucine substitution at position 6 and an N-ethylamide terminus at position 9, functioning as a high-potency LH-RH receptor agonist that down-regulates pituitary gonadotropin receptors and suppresses downstream steroidogenesis. As the international pharmaceutical sector expands beyond short-acting subcutaneous therapies toward 1-month, 3-month, and 6-month sustained-release biodegradable microspheres and subcutaneous implants, demand across oncology and reproductive endocrinology has intensified. Manufacturing facilities producing advanced parenteral therapeutics face acute quality and yield hurdles, particularly peptide chain truncation during continuous synthesis, aggregation during freeze-drying, and autocatalytic polymer cleavage induced by residual acidic reagents. Global pharmaceutical manufacturers, generic injectables formulators, and contract development organisations resolve these hurdles by sourcing through a certified commercial Leuprolide Acetate API supplier providing an active ingredient assay of ≥ 99.0% on an anhydrous, acetic acid-free basis. Sourcing high-purity leuprolide acetate active pharmaceutical ingredient with controlled trifluoroacetic acid (TFA) counter-ion levels (< 0.10%) protects polylactide-co-glycolide (PLGA) polymer matrices from premature core erosion, eliminates initial drug burst release in depot formulations, and secures long-term room-temperature stability. Every production batch undergoes comprehensive quality control testing and is supplied with batch-specific analytical dossiers confirming European Pharmacopoeia (Ph. Eur.) compliance, EU REACH registration, cGMP adherence, and WHO-GMP certification. We are an established Leuprolide Acetate API supplier with ≥ 99% purity globally for semi-finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Leuprolide Acetate COA/TDS/SDS. Beyond supply, we support partners with region-specific compliances, GMP quality assurance, and regulatory documentation through global supply chain capabilities and logistics coordination.

View Product
ATS 8

CAS No 125971-94-0

ATS 8

Category

Biocatalytic & Chiral Intermediates

Sub-Category

Enzymatic & Fermentation Intermediates

Description : We supply high-purity ATS - 8 (Atorvastatin Int.) to drive commercial production and biocatalytic process innovations across the international cardiovascular pharmaceutical, APIs, CDMO bioprocessing, and fine chemical manufacturing sectors. Recognised across global biopharma supply chains as atorvastatin side chain amine, (4R-cis)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester, this key chiral synthon contains two stereocentres critical for constructing the enantiomerically pure 3,5-dihydroxyheptanoic acid side chain of atorvastatin calcium. Produced via multi-step enzymatic biotransformation and green biocatalytic aldolase/halohydrin dehalogenase cascades, the chiral intermediate achieves enantiomeric excess values exceeding 99.5% (ee ≥ 99.5%), drastically reducing reliance on heavy-metal resolution catalysts and hazardous organometallic reagents. Global pharmaceutical manufacturers and bioprocess operators are replacing legacy multi-step chemical resolution routes with enzymatic biotransformations, selecting our strictly controlled 99.0% minimum purity grade to prevent diastereomeric contamination and downstream API crystallisation failures. Generic pharmaceutical producers partner with us as their certified global atorvastatin intermediate supplier to protect high-volume statin manufacturing campaigns from raw material impurities and cross-border supply chain bottlenecks. Choosing us as your trusted atorvastatin side chain amine supplier guarantees an advanced bioprocess intermediate that provides excellent batch-to-batch chemical yield, low residual solvent levels, and uniform crystalline powder stability during coupling reactions. Engineering and quality assurance teams can verify our strict material metrics by downloading our batch-specific ATS - 8 COA and TDS documentation, which details precise HPLC purity, chiral optical rotation, residual heavy-metal limits (≤ 10 ppm), and particle size distributions. Accessing our official ATS - 8 TDS ensures compliance with global standards, including European REACH registration, RoHS directives, cGMP compliance, and ISO 9001 quality management rules. Partner with us as your preferred ATS - 8 supplier to lock in commercial intermediate reserves and scale your active pharmaceutical ingredient lines

View Product